Paraneoplastic, Autoantibody Evaluation, Spinal Fluid
Use
Aiding in the diagnosis of paraneoplastic neurological autoimmune disorders related to carcinoma of lung, breast, ovary, thymoma, or Hodgkin lymphoma using spinal fluid specimens. It serves as a serological marker of a patient's immune response to specific cancers, which are often occult by standard imaging procedures. The detection of informative marker autoantibodies allows for early cancer diagnosis and can improve neurological morbidity and survival chances.
Special Instructions
This test is not our recommended test for patients suspected of autoimmune neurological disorders. Comprehensive neurological phenotype-specific autoimmune/paraneoplastic evaluation should be considered.
Limitations
The test does not contain all known clinically relevant antibodies for patients suspected of autoimmune neurological disorders. Serum is generally preferred for paraneoplastic autoantibodies; however, cerebrospinal fluid results can sometimes be positive even when serum results are negative. Submission of both CSF and serum specimens is recommended for simultaneous testing or to be held for testing only if serum is negative.
New York Approved
Methodology
Immunoassay (Indirect Immunofluorescence Assay)
Biomarkers
LOINC Codes
- 94818-2
- 90827-7
- 90815-2
- 44768-0
- 56959-0
- 90836-8
- 63216-6
- 90841-8
- 90843-4
- 90845-9
- 57771-8
- 48767-8
Result Turnaround Time
10-17 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
4 mL
Minimum Volume
2 mL
Container
Sterile vial
Collection Instructions
Preferred vial number 2; acceptable in any vial.
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |